Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: A randomized controlled clinical trial

Journal of Psychopharmacology

Volumn 26, Issue 7, 2012, Pages 1003-1009

  Tonstad, Serena ^a   Aubin, Henri Jean ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

Cannabinoid receptor blockers; endocannabinoids; nicotine addiction; obesity; smoking

Indexed keywords

PLACEBO; SURINABANT;

ADULT; AGED; ANXIETY; ARTICLE; ASTHENIA; BRAIN HEMORRHAGE; BURSITIS; CHOLELITHIASIS; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FALLING; FEMALE; HUMAN; HYPERHIDROSIS; INFLUENZA; INSOMNIA; IRRITABILITY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SMOKING CESSATION; TENDON RUPTURE; TOBACCO DEPENDENCE; TREATMENT OUTCOME; TROCHANTERIC BURSITIS; UPPER ABDOMINAL PAIN; UTERUS BLEEDING; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECURRENCE; SMOKING; SMOKING CESSATION; WEIGHT GAIN; YOUNG ADULT;

EID: 84862876244     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111431623     Document Type: Article

References (25)

1. Aubin HJ, Berlin I, Smadja E, West R. Factors associated with higher body mass index, weight concern, and weight gain in a multinational cohort study of smokers intending to quit. Int J Environ Res Public Health. 2009; 6: 943-957
2. Balerio GN, Aso E, Maldonado R. Role of cannabinoid system in the effects induced by nicotine on anxiety-like behavior in mice. Psychopharmacology. 2006; 184: 504-513 (Pubitemid 43255867)
3. Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Coch Data Syst Rev. 2007; 17: CD005353
4. Chinn S, Jarvis D, Melotti R, Luczynska C, Ackermann-Liebrich U, Antó JM, et al. Smoking cessation, lung function, and weight gain: a follow-up study. Lancet. 2005; 365: 1629-1635 (Pubitemid 40693412)
5. Christensen R, Kirstensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant; a meta-analysis of randomized trials. Lancet. 2007; 370: 1706-1713 (Pubitemid 350100788)
6. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005; 48: 3474-3477 (Pubitemid 40664098)
7. Cohen C, Perrault G, Griebel G, Soubrié P. Nicotine-associated cues maintain nicotine-seeking behavior in rates several weeks after nicotine withdrawal; reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology. 2005; 30: 145-155 (Pubitemid 40024408)
8. Davey Smith G, Bracha Y, Svendsen KH, Neaton JD, Haffner SM, Kuller LH. Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial. Ann Intern Med. 2005; 142: 313-322 (Pubitemid 40293404)
9. Doggrell SA. Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?. Exp Opin Investig Drugs. 2005; 14: 339-342 (Pubitemid 40520973)
10. Eisenberg MJ, Filion KB, Yavin D, Bélisle P, Mottillo S, Joseph L, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ. 2008; 179: 135-144 (Pubitemid 352020119)
11. Flegal KM, Troiano RP, Pamuk ER, Kuczmarski RJ, Campbell SM. The influence of smoking cessation on the prevalence of overweight in the United States. N Engl J Med. 1995; 333: 1165-1170
12. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA. 2006; 296: 47-55
13. Gonzalez S, Cascio MG, Fernandez-Ruiz J, Fezza F, Di Marzo V, Ramos JA. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res. 2002; 954: 73-81 (Pubitemid 35223443)
14. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991; 86: 1119-1127
15. Koster A, Leitzmann MF, Schatzkin A, Adams KF, van Eijk JT, Hollenbeck AR, et al. The combined relations of adiposity and smoking on mortality. Am J Clin Nutr. 2008; 88: 1206-1212
16. Lamota L, Bermudez-Silva FJ, Marco E-M, Llorente R, Gallego A, Rodríguez de Fonseca F, et al. Effects of adolescent nicotine and SR 147778 (surinabant) administration on food intake, somatic growth and metabolic parameters in rats. Neuropharmacology. 2008; 54: 194-205 (Pubitemid 350299415)
17. Le Foll B, Forget B, Aubin H-J, Goldberg SR. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from preclinical and clinical studies. Addict Biol. 2008; 13: 239-252 (Pubitemid 351692986)
18. Parsons AC, Shraim M, Inglis J, Aveyard P, Hajek P. Interventions for preventing weight gain after smoking cessation. Cochr Database Syst Rev. 2009; 1: CD006219
19. Pednekar MS, Gupta PC, Hebert JR, Hakama M. Joint effects of tobacco use and body mass on all-cause mortality in Mumbai, India: results from a population-based cohort study. Am J Epidemiol. 2008; 167: 330-340 (Pubitemid 351197585)
20. Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, Pério A, et al. SR147778 [5-(4-bromophenyl)-1-(2,4-dicholorophenyl)-4-ethyl-N-(1- piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. JPET. 2004; 310: 905-914 (Pubitemid 39108910)
21. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994; 350: 240-244 (Pubitemid 24268029)
22. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight; updated meta-analysis. Br Med J. 2007; 3335: 1194-1199 (Pubitemid 350273303)
23. Steinberg MB, Foulds J. Rimonabant for treating tobacco dependence. Vasc Health Risk Manage. 2007; 3: 307-311 (Pubitemid 47214974)
24. Toll BA, Katulak NA, McKee SA. Investigating the factor structure of the Questionnaire on Smoking Urges-Brief (QSU-Brief). Addict Behav. 2006; 31: 1231-1239
25. Warner C, Shoaib M. How does bupropion work as a smoking cessation aid?. Addict Biol. 2005; 10: 219-231 (Pubitemid 41306325)